[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-001", "question": "A 68-year-old man with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide presents with progressive dyspnea and fatigue. He has no chest pain or fever. His oxygen saturation is 88% on room air. CT pulmonary angiography shows no pulmonary embolism, but reveals diffuse ground-glass opacities with peripheral sparing. Bronchoalveolar lavage shows lymphocytic predominance with CD4:CD8 ratio of 0.3. Which of the following is the most appropriate next step in management?", "options": ["Discontinue enzalutamide and initiate high-dose corticosteroids", "Initiate empiric broad-spectrum antibiotics for atypical pneumonia", "Add abiraterone to his current regimen and continue enzalutamide", "Perform transbronchial biopsy to rule out lymphangitic carcinomatosis", "Start therapeutic-dose low-molecular-weight heparin for occult pulmonary embolism"], "answer": "A", "answer_index": 0, "explanation": "This presentation is classic for enzalutamide-induced interstitial pneumonitis, which typically presents with subacute dyspnea, ground-glass opacities on CT, and a lymphocytic BAL with low CD4:CD8 ratio. Immediate discontinuation of the offending agent and initiation of corticosteroids is the standard management. Antibiotics are not indicated without infectious signs, and adding abiraterone would exacerbate the drug-induced lung injury.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with mCRPC on enzalutamide presenting with hypoxic respiratory failure, diffuse ground-glass opacities (GGOs) with peripheral sparing, and a lymphocytic BAL with a low CD4:CD8 ratio (0.3). This clinical picture is characteristic of drug-induced pneumonitis (DIP) manifesting as a hypersensitivity pneumonitis-like reaction (or NSIP pattern). Enzalutamide is a known, albeit rare, cause of ILD/pneumonitis. The low CD4:CD8 ratio supports a hypersensitivity-type mechanism and argues against sarcoidosis (typically high ratio). While opportunistic infection (e.g., PJP) is a differential in cancer patients, the absence of fever and the specific framing of the drug side effect point toward DIP. Furthermore, Option B suggests antibiotics for 'atypical pneumonia' (bacteria), which is not the correct treatment for PJP (TMP-SMX), making Option A the only defensible management step for the most likely diagnosis. Discontinuing the offending agent and starting corticosteroids is the standard of care for severe DIP. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with mCRPC on enzalutamide presenting with hypoxic respiratory failure, diffuse ground-glass opacities (GGOs) with peripheral sparing, and a lymphocytic BAL with a low CD4:CD8 ratio (0.3). This clinical picture is characteristic of drug-induced pneumonitis (DIP) manifesting as a hypersensitivity pneumonitis-like reaction (or NSIP pattern). Enzalutamide is a known, albeit rare, cause of ILD/pneumonitis. The low CD4:CD8 ratio supports a hypersensitivity-type mechanism and argues against sarcoidosis (typically high ratio). While opportunistic infection (e.g., PJP) is a differential in cancer patients, the absence of fever and the specific framing of the drug side effect point toward DIP. Furthermore, Option B suggests antibiotics for 'atypical pneumonia' (bacteria), which is not the correct treatment for PJP (TMP-SMX), making Option A the only defensible management step for the most likely diagnosis. Discontinuing the offending agent and starting corticosteroids is the standard of care for severe DIP. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-002", "question": "A 4-month-old previously healthy infant presents with acute onset of irritability, vomiting, and lethargy. Physical examination reveals a bulging anterior fontanelle, retinal hemorrhages, and no focal neurologic deficits. Non-contrast head CT shows bilateral subdural hematomas of different ages. The infant's coagulation studies and metabolic panel are normal. Which of the following additional findings would most strongly support a diagnosis of glutaric aciduria type 1 rather than non-accidental trauma?", "options": ["Metaphyseal corner fractures on skeletal survey", "Elevated serum ammonia level", "Frontotemporal atrophy with widened Sylvian fissures on MRI", "Subarachnoid hemorrhage extending into the posterior fossa", "Elevated urine organic acids showing 3-hydroxyglutaric aciduria"], "answer": "E", "answer_index": 4, "explanation": "While glutaric aciduria type 1 can mimic non-accidental trauma with acute encephalopathy and subdural hematomas, the definitive diagnosis requires demonstration of elevated urine organic acids, specifically 3-hydroxyglutaric aciduria. Frontotemporal atrophy (option C) is a characteristic neuroimaging finding but is not diagnostic. Metaphyseal fractures strongly suggest abuse, while elevated ammonia suggests a different metabolic disorder.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item addresses the differential diagnosis between Non-Accidental Trauma (NAT) and Glutaric Aciduria Type 1 (GA1) in an infant with subdural hematomas. The question asks for the finding that most strongly supports GA1. Option E (3-hydroxyglutaric aciduria) is the definitive biochemical diagnostic marker for GA1, making it the indisputable best answer. Option C (frontotemporal atrophy) is a characteristic imaging finding that provides the mechanism for subdural hematomas in GA1 (widened Sylvian fissures stretching bridging veins), but it is a supportive sign rather than a confirmatory diagnostic test. Option A supports NAT. The stem includes retinal hemorrhages, which are highly specific for NAT and generally considered absent in pure GA1; while this makes the clinical vignette somewhat controversial or atypical for a 'pure' GA1 case, it does not logically invalidate the question, which asks to identify the evidence for the metabolic disorder. The distinction between a suggestive imaging sign (C) and a diagnostic metabolite (E) is a standard and valid board-exam discriminator.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item addresses the differential diagnosis between Non-Accidental Trauma (NAT) and Glutaric Aciduria Type 1 (GA1) in an infant with subdural hematomas. The question asks for the finding that most strongly supports GA1. Option E (3-hydroxyglutaric aciduria) is the definitive biochemical diagnostic marker for GA1, making it the indisputable best answer. Option C (frontotemporal atrophy) is a characteristic imaging finding that provides the mechanism for subdural hematomas in GA1 (widened Sylvian fissures stretching bridging veins), but it is a supportive sign rather than a confirmatory diagnostic test. Option A supports NAT. The stem includes retinal hemorrhages, which are highly specific for NAT and generally considered absent in pure GA1; while this makes the clinical vignette somewhat controversial or atypical for a 'pure' GA1 case, it does not logically invalidate the question, which asks to identify the evidence for the metabolic disorder. The distinction between a suggestive imaging sign (C) and a diagnostic metabolite (E) is a standard and valid board-exam discriminator.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-003", "question": "A 55-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who failed CAR T-cell therapy 3 months ago presents with new-onset confusion and myoclonus. MRI brain shows symmetric diffusion restriction in the bilateral thalami, basal ganglia, and cerebral cortex. EEG demonstrates periodic sharp wave complexes. CSF shows 12 white cells/mm³ (90% lymphocytes), normal glucose, and elevated protein at 80 mg/dL. Which of the following is the most likely causative agent?", "options": ["Tafasitamab", "Polatuzumab vedotin", "Tisagenlecleucel", "Blinatumomab", "Brentuximab vedotin"], "answer": "C", "answer_index": 2, "explanation": "This presentation is classic for CAR T-cell therapy-related immune effector cell-associated neurotoxicity syndrome (ICANS), which can occur weeks to months after treatment. The MRI pattern of symmetric deep gray matter and cortical involvement with corresponding EEG findings is characteristic. Tisagenlecleucel is a CD19-directed CAR T-cell therapy used in DLBCL. The other agents are monoclonal antibodies or antibody-drug conjugates not typically associated with this specific delayed neurotoxicity pattern.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette presents a textbook description of Creutzfeldt-Jakob Disease (CJD), characterized by the classic triad of rapid dementia, myoclonus, and periodic sharp wave complexes (PSWC) on EEG, along with pathognomonic MRI findings of symmetric diffusion restriction in the basal ganglia and cortex ('cortical ribboning'). The question asks for the causative agent among lymphoma therapies, and the key (Tisagenlecleucel) suggests this is delayed ICANS. This is medically inaccurate. ICANS typically occurs within days to weeks (median ~4-5 days), not 3 months post-infusion as a new onset event. More importantly, ICANS does not present with the specific EEG (PSWC) or MRI (cortical ribboning) features of CJD. By describing a patient with CJD but attributing the cause to a CAR T-cell therapy via a mechanism that does not fit the description, the item contains a fatal medical error. No option provided causes the condition described in the vignette. The item is unsolvable because the clinical picture contradicts the intended etiology.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette presents a textbook description of Creutzfeldt-Jakob Disease (CJD), characterized by the classic triad of rapid dementia, myoclonus, and periodic sharp wave complexes (PSWC) on EEG, along with pathognomonic MRI findings of symmetric diffusion restriction in the basal ganglia and cortex ('cortical ribboning'). The question asks for the causative agent among lymphoma therapies, and the key (Tisagenlecleucel) suggests this is delayed ICANS. This is medically inaccurate. ICANS typically occurs within days to weeks (median ~4-5 days), not 3 months post-infusion as a new onset event. More importantly, ICANS does not present with the specific EEG (PSWC) or MRI (cortical ribboning) features of CJD. By describing a patient with CJD but attributing the cause to a CAR T-cell therapy via a mechanism that does not fit the description, the item contains a fatal medical error. No option provided causes the condition described in the vignette. The item is unsolvable because the clinical picture contradicts the intended etiology.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-004", "question": "A critically ill patient with septic shock on norepinephrine (0.3 mcg/kg/min) and vasopressin (0.03 units/min) develops refractory hypotension. Transthoracic echocardiogram shows a hyperdynamic left ventricle with collapsing mitral inflow pattern. Which of the following interventions is most likely to improve hemodynamics without increasing myocardial oxygen demand?", "options": ["Initiate dobutamine infusion at 5 mcg/kg/min", "Add phenylephrine infusion to target MAP >65 mmHg", "Administer 500 mL 5% albumin bolus", "Start angiotensin II infusion at 20 ng/kg/min", "Increase norepinephrine to 0.5 mcg/kg/min"], "answer": "D", "answer_index": 3, "explanation": "The echocardiographic findings suggest distributive shock with relative hypovolemia. Angiotensin II acts via AT1 receptors to cause vasoconstriction without significant inotropic effects, making it ideal for this scenario without increasing myocardial oxygen demand. Dobutamine increases myocardial demand, phenylephrine causes pure alpha-agonism with potential reflex bradycardia, fluid bolus may be insufficient in vasoplegic shock, and increasing norepinephrine adds beta-1 effects that increase oxygen consumption.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient in septic shock with echocardiographic findings of a 'hyperdynamic left ventricle' and 'collapsing' patterns. These are classic signs of significant hypovolemia (preload dependence). The standard of care for a hypotensive patient with a hyperdynamic, underfilled heart is volume resuscitation. Therefore, Option C (albumin bolus) is the most appropriate next step to improve hemodynamics via the Frank-Starling mechanism. While Angiotensin II (Option D) is a valid third-line vasopressor for high-output vasodilatory shock (ATHOS-3 criteria), it is clinically inappropriate to add a potent vasoconstrictor to a hypovolemic patient ('squeeze before fill') as this can worsen perfusion and precipitate LVOT obstruction. Furthermore, Angiotensin II increases afterload, which increases myocardial wall tension and oxygen demand (MVO2), contradicting the stem's constraint to avoid increasing MVO2. Volume resuscitation typically reduces MVO2 by lowering heart rate and catecholamine drive. Consequently, Option C is the superior answer based on the physiology presented. The provided key (D) ignores the specific echocardiographic evidence of hypovolemia.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient in septic shock with echocardiographic findings of a 'hyperdynamic left ventricle' and 'collapsing' patterns. These are classic signs of significant hypovolemia (preload dependence). The standard of care for a hypotensive patient with a hyperdynamic, underfilled heart is volume resuscitation. Therefore, Option C (albumin bolus) is the most appropriate next step to improve hemodynamics via the Frank-Starling mechanism. While Angiotensin II (Option D) is a valid third-line vasopressor for high-output vasodilatory shock (ATHOS-3 criteria), it is clinically inappropriate to add a potent vasoconstrictor to a hypovolemic patient ('squeeze before fill') as this can worsen perfusion and precipitate LVOT obstruction. Furthermore, Angiotensin II increases afterload, which increases myocardial wall tension and oxygen demand (MVO2), contradicting the stem's constraint to avoid increasing MVO2. Volume resuscitation typically reduces MVO2 by lowering heart rate and catecholamine drive. Consequently, Option C is the superior answer based on the physiology presented. The provided key (D) ignores the specific echocardiographic evidence of hypovolemia.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-005", "question": "A 7-year-old boy presents with acute cerebellar ataxia following varicella infection 2 weeks prior. MRI shows T2 hyperintensity restricted to the cerebellar hemispheres. CSF demonstrates 15 lymphocytes/mm³, normal glucose, and elevated IgG index. Which of the following autoantibodies is most specific for this condition?", "options": ["Anti-GAD65", "Anti-Hu", "Anti-Yo", "Anti-Tr/DNER", "Anti-mGluR1"], "answer": "D", "answer_index": 3, "explanation": "Post-varicella acute cerebellar ataxia is associated with anti-Tr/DNER (delta/notch-like epidermal growth factor-related receptor) antibodies in a significant proportion of cases. This antibody is highly specific for paraneoplastic cerebellar degeneration in Hodgkin lymphoma but also occurs in post-infectious contexts. Anti-Yo and anti-Hu are associated with gynecological/breast cancers and small cell lung cancer respectively. Anti-mGluR1 is seen in Hodgkin-related ataxia, while anti-GAD65 is associated with stiff-person syndrome.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: K (Miskeyed). Verdict: Miskeyed; Option E is scientifically superior to Key D. \\n\\nThe vignette describes a child with acute cerebellar ataxia following varicella, a condition that is typically a clinical diagnosis and seronegative. However, if an autoantibody is implicated in post-infectious cerebellar ataxia (specifically post-varicella), literature supports **Anti-mGluR1** (Option E) or Anti-GluRdelta2 (not listed). The keyed answer, **Anti-Tr/DNER** (Option D), is classically and highly specifically associated with paraneoplastic cerebellar degeneration in the context of Hodgkin lymphoma. The explanation's claim that Anti-Tr occurs in a 'significant proportion' of post-varicella cases contradicts standard medical knowledge, likely confusing it with Anti-mGluR1 or Anti-GluRdelta2. Therefore, Option E is the most defensible answer among the choices provided, making the item miskeyed and medically inaccurate as written. \\n\\nMinimal Fix: Change the clinical vignette to an adult with Hodgkin lymphoma to match Key D, or change the Key to E (and update the rationale to reflect the mGluR1/post-infectious association).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). Verdict: Miskeyed; Option E is scientifically superior to Key D. \n\nThe vignette describes a child with acute cerebellar ataxia following varicella, a condition that is typically a clinical diagnosis and seronegative. However, if an autoantibody is implicated in post-infectious cerebellar ataxia (specifically post-varicella), literature supports **Anti-mGluR1** (Option E) or Anti-GluRdelta2 (not listed). The keyed answer, **Anti-Tr/DNER** (Option D), is classically and highly specifically associated with paraneoplastic cerebellar degeneration in the context of Hodgkin lymphoma. The explanation's claim that Anti-Tr occurs in a 'significant proportion' of post-varicella cases contradicts standard medical knowledge, likely confusing it with Anti-mGluR1 or Anti-GluRdelta2. Therefore, Option E is the most defensible answer among the choices provided, making the item miskeyed and medically inaccurate as written. \n\nMinimal Fix: Change the clinical vignette to an adult with Hodgkin lymphoma to match Key D, or change the Key to E (and update the rationale to reflect the mGluR1/post-infectious association).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-006", "question": "A 42-year-old woman with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) achieves complete morphological remission after induction chemotherapy. Minimal residual disease (MRD) testing by flow cytometry shows 0.01% blasts. Which of the following factors would most strongly indicate proceeding to allogeneic hematopoietic stem cell transplantation in first complete remission rather than continuing with chemotherapy plus a tyrosine kinase inhibitor?", "options": ["Presence of IKZF1 deletion", "Age >40 years", "MRD positivity after consolidation therapy", "White blood cell count >30,000/μL at diagnosis", "Presence of additional cytogenetic abnormalities besides t(9;22)"], "answer": "C", "answer_index": 2, "explanation": "In Ph+ ALL, MRD positivity after consolidation therapy is the strongest predictor of poor outcome with chemotherapy/TKI alone and is a clear indication for allogeneic transplantation in first remission. While age >40, high WBC, IKZF1 deletion, and additional abnormalities are adverse prognostic factors, contemporary TKI-based regimens can overcome many of these. Persistent MRD after intensive therapy indicates resistant disease requiring transplant for cure.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The item accurately tests the risk-stratified management of Philadelphia chromosome-positive (Ph+) ALL in the tyrosine kinase inhibitor (TKI) era. While Ph+ ALL was historically an absolute indication for allogeneic HSCT, contemporary practice uses Minimal Residual Disease (MRD) response to guide the decision. Patients achieving deep molecular response (CMR) with TKI+chemotherapy often have outcomes comparable to transplant without the associated toxicity. Persistent MRD positivity, particularly after consolidation therapy (Option C), is the strongest predictor of relapse and the definitive indication for HSCT in first remission. Options A (IKZF1 deletion), B (Age), D (WBC), and E (Cytogenetics) are valid baseline risk factors, but dynamic risk assessment via MRD supersedes them in current algorithms. The distinction between the vignette's current state (post-induction) and the decision trigger (post-consolidation) correctly identifies the longitudinal criteria required for the transplant decision.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The item accurately tests the risk-stratified management of Philadelphia chromosome-positive (Ph+) ALL in the tyrosine kinase inhibitor (TKI) era. While Ph+ ALL was historically an absolute indication for allogeneic HSCT, contemporary practice uses Minimal Residual Disease (MRD) response to guide the decision. Patients achieving deep molecular response (CMR) with TKI+chemotherapy often have outcomes comparable to transplant without the associated toxicity. Persistent MRD positivity, particularly after consolidation therapy (Option C), is the strongest predictor of relapse and the definitive indication for HSCT in first remission. Options A (IKZF1 deletion), B (Age), D (WBC), and E (Cytogenetics) are valid baseline risk factors, but dynamic risk assessment via MRD supersedes them in current algorithms. The distinction between the vignette's current state (post-induction) and the decision trigger (post-consolidation) correctly identifies the longitudinal criteria required for the transplant decision.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-007", "question": "A 65-year-old man with atrial fibrillation on apixaban presents with acute onset of aphasia and right hemiparesis. CT head shows a 3 cm left MCA territory infarct with no hemorrhage. Last apixaban dose was 4 hours ago. NIH Stroke Scale is 18. Which of the following is the most appropriate acute intervention?", "options": ["Administer intravenous tissue plasminogen activator immediately", "Give 4-factor prothrombin complex concentrate followed by tPA", "Perform emergent mechanical thrombectomy without thrombolysis", "Administer andexanet alfa followed by mechanical thrombectomy", "Give idarucizumab empirically followed by mechanical thrombectomy"], "answer": "C", "answer_index": 2, "explanation": "For large vessel occlusion strokes in patients on direct oral anticoagulants (DOACs) with recent dosing, mechanical thrombectomy without thrombolysis is recommended due to the increased risk of hemorrhagic transformation with tPA. Andexanet alfa is a reversal agent for factor Xa inhibitors but is not routinely recommended prior to thrombectomy unless there is life-threatening bleeding. Idarucizumab is for dabigatran reversal. PCC before tPA still carries bleeding risk and delays intervention.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with a severe acute ischemic stroke (NIHSS 18) and clinical features strongly suggestive of a Large Vessel Occlusion (LVO) in the left MCA territory. The patient took apixaban 4 hours ago, which renders him ineligible for IV tissue plasminogen activator (tPA) due to active anticoagulation (guidelines generally exclude tPA if DOAC taken < 48 hours). Consequently, Option A is contraindicated. There is no current evidence supporting the use of reversal agents (PCC or Andexanet alfa) to facilitate tPA administration in ischemic stroke (Options B and D), and doing so carries pro-thrombotic risks. Idarucizumab (Option E) is the reversal agent for dabigatran, not apixaban. Mechanical thrombectomy without thrombolysis (Option C) is the standard of care for patients with LVO who are ineligible for tPA. Although the stem mentions a '3 cm infarct' (implying some established core), the high NIHSS suggests a large penumbra, making thrombectomy the only appropriate and defensible intervention among the choices.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with a severe acute ischemic stroke (NIHSS 18) and clinical features strongly suggestive of a Large Vessel Occlusion (LVO) in the left MCA territory. The patient took apixaban 4 hours ago, which renders him ineligible for IV tissue plasminogen activator (tPA) due to active anticoagulation (guidelines generally exclude tPA if DOAC taken < 48 hours). Consequently, Option A is contraindicated. There is no current evidence supporting the use of reversal agents (PCC or Andexanet alfa) to facilitate tPA administration in ischemic stroke (Options B and D), and doing so carries pro-thrombotic risks. Idarucizumab (Option E) is the reversal agent for dabigatran, not apixaban. Mechanical thrombectomy without thrombolysis (Option C) is the standard of care for patients with LVO who are ineligible for tPA. Although the stem mentions a '3 cm infarct' (implying some established core), the high NIHSS suggests a large penumbra, making thrombectomy the only appropriate and defensible intervention among the choices.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-008", "question": "A 3-year-old child with DiGeorge syndrome (22q11.2 deletion) presents with hypocalcemic seizures. Correction of calcium with intravenous calcium gluconate and calcitriol is initiated. Which of the following immunologic parameters, if present, would be an absolute contraindication to live viral vaccination?", "options": ["CD4+ T cell count <500 cells/μL", "Absent thymic shadow on chest radiograph", "Low but detectable T cell receptor excision circles (TRECs)", "Severely reduced proliferative response to phytohemagglutinin", "Complete absence of CD3+ T cells by flow cytometry"], "answer": "E", "answer_index": 4, "explanation": "Complete absence of CD3+ T cells indicates severe combined immunodeficiency (SCID) phenotype within DiGeorge spectrum, which is an absolute contraindication to live vaccines due to risk of disseminated infection. Reduced proliferative responses (option D) indicate functional impairment but not complete absence. Low TRECs suggest poor thymic output but not necessarily SCID. CD4 count and thymic shadow are not definitive contraindications alone.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item asks for an absolute contraindication to live viral vaccination in a 3-year-old with DiGeorge syndrome. According to standard guidelines (ACIP, AAP Red Book, Clinical Immunology Society), live vaccines are contraindicated in DiGeorge patients with severe immunosuppression, defined as CD4+ T-cell counts <500 cells/μL (Option A) or severely reduced mitogen proliferative responses (Option D). Option E (Complete absence of T cells) represents the SCID phenotype ('Complete DiGeorge'), which is also a contraindication. Therefore, Options A, D, and E are all medically correct answers, as any of these findings would preclude vaccination. The provided rationale incorrectly suggests that only the most severe phenotype (E) is a contraindication, ignoring that severe partial defects (A and D) are also absolute contraindications due to the risk of disseminated infection. This results in multiple defensible answers. To fix this, options A and D should be changed to values indicating immunocompetence (e.g., 'CD4+ count >500' or 'Normal mitogen response') to make E the unique correct key.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item asks for an absolute contraindication to live viral vaccination in a 3-year-old with DiGeorge syndrome. According to standard guidelines (ACIP, AAP Red Book, Clinical Immunology Society), live vaccines are contraindicated in DiGeorge patients with severe immunosuppression, defined as CD4+ T-cell counts <500 cells/μL (Option A) or severely reduced mitogen proliferative responses (Option D). Option E (Complete absence of T cells) represents the SCID phenotype ('Complete DiGeorge'), which is also a contraindication. Therefore, Options A, D, and E are all medically correct answers, as any of these findings would preclude vaccination. The provided rationale incorrectly suggests that only the most severe phenotype (E) is a contraindication, ignoring that severe partial defects (A and D) are also absolute contraindications due to the risk of disseminated infection. This results in multiple defensible answers. To fix this, options A and D should be changed to values indicating immunocompetence (e.g., 'CD4+ count >500' or 'Normal mitogen response') to make E the unique correct key.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-009", "question": "A patient with glioblastoma on temozolomide and dexamethasone develops progressive headache, visual changes, and diabetes insipidus. MRI shows thickening and enhancement of the pituitary stalk with loss of the posterior pituitary bright spot. CSF cytology is negative. Which of the following findings would most strongly support a diagnosis of lymphocytic hypophysitis over pituitary metastasis?", "options": ["Presence of anti-pituitary antibodies", "Elevated CSF beta-2 transferrin", "Simultaneous involvement of the pineal gland", "Rapid improvement with high-dose corticosteroids", "Association with other autoimmune endocrine deficiencies"], "answer": "E", "answer_index": 4, "explanation": "Lymphocytic hypophysitis frequently presents with other autoimmune endocrine deficiencies (thyroiditis, adrenalitis, diabetes mellitus type 1), while pituitary metastases typically occur in isolation. Anti-pituitary antibodies have poor sensitivity/specificity. CSF beta-2 transferrin indicates CSF leak. Pineal involvement suggests germinoma. Steroid responsiveness occurs in both conditions but is more dramatic in hypophysitis; however, association with other autoimmune conditions is more specific.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question asks to differentiate lymphocytic hypophysitis (LH) from pituitary metastasis. Option E is the correct best answer, as LH is an autoimmune condition frequently associated with other autoimmune disorders (e.g., thyroiditis, adrenalitis) in the context of polyglandular autoimmune syndromes. Option A (anti-pituitary antibodies) is a plausible distractor, but these assays often lack sensitivity/specificity and are less clinically relied upon than the presence of concurrent autoimmune disease. Option C (pineal involvement) strongly suggests germinoma. Option D (steroid response) is a poor discriminator here because the patient is already on dexamethasone (yet developed symptoms) and peritumoral edema associated with metastases can also respond to steroids. The vignette contains a minor clinical artificiality: spontaneous LH developing in a patient with glioblastoma (GBM) who is already on dexamethasone (which treats LH) is highly improbable. Additionally, GBM typically affects the pituitary via direct extension or leptomeningeal spread rather than hematogenous 'metastasis.' However, within the constraints of the theoretical discrimination task, Option E is the only choice that mechanistically supports an autoimmune etiology over a neoplastic one.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question asks to differentiate lymphocytic hypophysitis (LH) from pituitary metastasis. Option E is the correct best answer, as LH is an autoimmune condition frequently associated with other autoimmune disorders (e.g., thyroiditis, adrenalitis) in the context of polyglandular autoimmune syndromes. Option A (anti-pituitary antibodies) is a plausible distractor, but these assays often lack sensitivity/specificity and are less clinically relied upon than the presence of concurrent autoimmune disease. Option C (pineal involvement) strongly suggests germinoma. Option D (steroid response) is a poor discriminator here because the patient is already on dexamethasone (yet developed symptoms) and peritumoral edema associated with metastases can also respond to steroids. The vignette contains a minor clinical artificiality: spontaneous LH developing in a patient with glioblastoma (GBM) who is already on dexamethasone (which treats LH) is highly improbable. Additionally, GBM typically affects the pituitary via direct extension or leptomeningeal spread rather than hematogenous 'metastasis.' However, within the constraints of the theoretical discrimination task, Option E is the only choice that mechanistically supports an autoimmune etiology over a neoplastic one.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed125", "question_id": "20251205T084024622Z_deepseek-v3.2_seed125-010", "question": "A neonate born at 32 weeks gestation develops necrotizing enterocolitis (NEC) on day 10 of life. During laparotomy, approximately 40% of the small bowel appears necrotic. Which of the following intraoperative findings would mandate creation of a high jejunostomy rather than primary anastomosis?", "options": ["Involvement of the ileocecal valve", "Necrosis extending to within 5 cm of the ligament of Treitz", "Presence of pneumatosis intestinalis in the remaining bowel", "Concurrent isolated perforation of the gastric fundus", "Development of abdominal compartment syndrome during surgery"], "answer": "B", "answer_index": 1, "explanation": "Necrosis extending to within 5 cm of the ligament of Treitz indicates near-total small bowel loss, requiring high jejunostomy to preserve the maximal possible length of viable bowel for future adaptation and prevent anastomotic leakage in compromised tissue. Ileocecal valve involvement is important for absorption but doesn't dictate anastomosis vs ostomy. Pneumatosis may be present in non-necrotic bowel. Gastric perforation is managed separately. Abdominal compartment syndrome may require temporary closure but not necessarily jejunostomy.", "generator_model": "deepseek-v3.2", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is logically invalid due to an internal contradiction and debatable medical reasoning. \\n\\n1. **Contradiction:** The stem explicitly states that \\\"approximately 40% of the small bowel appears necrotic.\\\" However, the keyed answer (B) and its rationale (\\\"indicates near-total small bowel loss\\\") assume the necrosis extends from the distal bowel all the way to within 5 cm of the ligament of Treitz. In a neonate, this would represent >90% necrosis, directly contradicting the \\\"40%\\\" premise in the stem. If the necrosis were only the proximal 40%, significant distal bowel would remain, negating the \\\"near-total loss\\\" rationale.\\n\\n2. **Defensibility:** Option E (Abdominal Compartment Syndrome) is a recognized absolute contraindication to primary anastomosis (mandating damage control/open abdomen), whereas proximal necrosis (Option B) often prompts surgeons to *attempt* anastomosis to avoid the severe morbidity of a high-output jejunostomy. Thus, E is a stronger medical reason to avoid anastomosis than B, yet B is keyed based on the contradictory \\\"near-total\\\" assumption.\\n\\n3. **Fix:** The stem must be consistent (e.g., change \\\"40%\\\" to \\\"near-total\\\" or \\\"extensive\\\"). The question should clarify if it asks for the *type* of stoma (anatomical) or the *reason* to avoid anastomosis.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is logically invalid due to an internal contradiction and debatable medical reasoning. \n\n1. **Contradiction:** The stem explicitly states that \"approximately 40% of the small bowel appears necrotic.\" However, the keyed answer (B) and its rationale (\"indicates near-total small bowel loss\") assume the necrosis extends from the distal bowel all the way to within 5 cm of the ligament of Treitz. In a neonate, this would represent >90% necrosis, directly contradicting the \"40%\" premise in the stem. If the necrosis were only the proximal 40%, significant distal bowel would remain, negating the \"near-total loss\" rationale.\n\n2. **Defensibility:** Option E (Abdominal Compartment Syndrome) is a recognized absolute contraindication to primary anastomosis (mandating damage control/open abdomen), whereas proximal necrosis (Option B) often prompts surgeons to *attempt* anastomosis to avoid the severe morbidity of a high-output jejunostomy. Thus, E is a stronger medical reason to avoid anastomosis than B, yet B is keyed based on the contradictory \"near-total\" assumption.\n\n3. **Fix:** The stem must be consistent (e.g., change \"40%\" to \"near-total\" or \"extensive\"). The question should clarify if it asks for the *type* of stoma (anatomical) or the *reason* to avoid anastomosis.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}]